Intuitive Surgical Is Up 7% in the Last 6 Months. Here’s Where the Stock Could Go in 2026

Intuitive Surgical (ISRG) has seen its stock rise 7% in the past six months, driven by strong procedure growth, adoption of da Vinci 5, and increasing recurring revenue. The company delivered robust Q4 results, with revenue up 19% and pro forma EPS rising to $2.53. A valuation model suggests a target price of $733, implying a 46% upside, based on projected revenue growth of 13.9% and operating margins of 38.7% by 2030, indicating that ISRG appears undervalued.